Fulgent Genetics, Inc. (FLGT) stock
FLGTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3047% below fair value
$24.21+0.14 (+0.56%)
Close on Nov 17, 2026Market cap $666.15MP/E –Yield –
Fulgent Genetics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Fulgent Genetics's price to sales ratio was 2.2× on Nov 11, 2026, against 2.9× a year earlier. Over the last 5 years it ranged from 1.1× to 3.2×, with a median of 2.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 2.2× | −0.4 |
| 2025 | Dec 31, 2025 | 2.6× | +0.5 |
| 2024 | Dec 31, 2024 | 2.0× | −1.0 |
| 2023 | Dec 29, 2023 | 3.0× | +1.9 |
| 2022 | Dec 30, 2022 | 1.1× | −1.8 |
| 2021 | Dec 31, 2021 | 2.9× | −6.1 |
| 2020 | Dec 31, 2020 | 9.0× | +0.9 |
| 2019 | Dec 31, 2019 | 8.1× | +5.2 |
| 2018 | Dec 31, 2018 | 2.9× | −1.0 |
| 2017 | Dec 29, 2017 | 3.8× | −5.9 |
| 2016 | Dec 30, 2016 | 9.7× | – |
See a number that looks wrong?